Recent studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing significant effects in treating obesity and related non-insulin-dependent condition. Animal data suggest a novel action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/